{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:21:59Z","timestamp":1785871319821,"version":"3.56.0"},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Limited data are available regarding second\u2010line (2\u00a0L) treatment for advanced or metastatic biliary tract cancers (BTC) in the US real\u2010world setting. This study explores the rapidly evolving and growing treatment landscape in the 2\u00a0L setting for advanced or metastatic BTC with a large cohort of patients treated in a community oncology setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adult patients with BTC initiating 2\u00a0L treatment after a platinum\u2010containing first\u2010line between 1\/1\/10\u2010 and 6\/30\/19 were identified from the US Oncology Network electronic healthcare record database and followed through 12\/31\/19. Baseline patient and treatment characteristics were analyzed descriptively, including overall response rate (ORR) in the real\u2010world clinical setting. Kaplan\u2013Meier methods were used to measure duration of response, progression\u2010free survival (PFS), and overall survival (OS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall population (<jats:italic>N<\/jats:italic>\u00a0=\u00a0160) included 74 patients (46.3%) with intrahepatic cholangiocarcinoma, 41 (25.6%) with extrahepatic cholangiocarcinoma, and 45 (28.1%) with gallbladder cancer. Thirty unique 2\u00a0L regimens were recorded for the study population, with folinic acid, fluorouracil and oxaliplatin (FOLFOX, 34.4%) and capecitabine monotherapy (20.0%) being the most common. ORR was 7.5% (95% CI, 3.9%\u201312.7%). From 2\u00a0L initiation, median PFS was 2.8\u00a0months (95% CI, 2.4\u20133.3\u00a0months), and median OS was 5.2\u00a0months (95% CI, 4.2\u20136.7\u00a0months).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Results from this study provide real\u2010world evidence that although patients treated in the community oncology setting receive a wide variety of 2\u00a0L treatments, the regimens are consistent with those recommended by guidelines. Although responses are observed with 2\u00a0L treatment, duration is brief and associated with poor OS in patients with advanced or metastatic disease.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.5282","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T10:40:28Z","timestamp":1666262428000},"page":"4195-4205","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real\u2010world outcomes among patients with advanced or metastatic biliary tract cancers initiating second\u2010line treatment"],"prefix":"10.1002","volume":"12","author":[{"given":"David P.","family":"Cosgrove","sequence":"first","affiliation":[{"name":"Compass Oncology, The US Oncology Network  Vancouver Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily S.","family":"Reese","sequence":"additional","affiliation":[{"name":"EMD Serono  Billerica Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Fulcher","sequence":"additional","affiliation":[{"name":"Ontada  The Woodlands Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah S.","family":"Bobiak","sequence":"additional","affiliation":[{"name":"EMD Serono  Billerica Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois\u2010Xavier","family":"Lamy","sequence":"additional","affiliation":[{"name":"Healthcare Business of Merck KGaA  Darmstadt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Allignol","sequence":"additional","affiliation":[{"name":"Healthcare Business of Merck KGaA  Darmstadt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marley","family":"Boyd","sequence":"additional","affiliation":[{"name":"Ontada  The Woodlands Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed H.","family":"Mahmoudpour","sequence":"additional","affiliation":[{"name":"Healthcare Business of Merck KGaA  Darmstadt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00153-7"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051237"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31942"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721"},{"key":"e_1_2_10_7_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology.Hepatobiliary Cancers Version 2.2022updated July 15 2022.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hepatobiliary.pdf."},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00027-9"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29471"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.4_suppl.497"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-015-0267-x"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3353-2"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143507"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32463"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v12.i11.83"},{"issue":"6","key":"e_1_2_10_16_1","first-page":"408","article-title":"Second\u2010line systemic treatment for advanced cholangiocarcinoma","volume":"5","author":"Rogers JE","year":"2014","journal-title":"J Gastrointest Oncol"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.4_suppl.381"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.4_suppl.543"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000789"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.09.517"},{"key":"e_1_2_10_21_1","unstructured":"The US Oncology Network [updated 2022]."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.5282","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.5282","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.5282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T16:55:34Z","timestamp":1747673734000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.5282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1002\/cam4.5282"],"URL":"https:\/\/doi.org\/10.1002\/cam4.5282","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]},"assertion":[{"value":"2022-03-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}